Abstract
Objective
To evaluate the achievement of minimal disease activity (MDA) and very low disease activity (VLDA) in patients with psoriatic arthritis (PsA) treated in a real-world clinical setting with biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).
Methods
This study included patients with a diagnosis of PsA treated with an approved b/tsDMARD and enrolled in the CorEvitas PsA/Spondyloarthritis (SpA) Registry (March 2013-September 2023). MDA/VLDA achievement was assessed at the follow-up registry visit, 6 (range: 5-9) months post index (b/tsDMARD initiation).
Results
At the follow-up registry visit, 17.68% (370/2093) and 7.51% (187/2491) of patients achieved MDA and VLDA, respectively. Baseline characteristics, including female sex, higher baseline fatigue and pain scores, and previous treatment with b/tsDMARDs were associated with a lower likelihood of achieving MDA/VLDA. Higher EQ-5D-3L scores and b/tsDMARD monotherapy were associated with a higher likelihood of achieving MDA. Among MDA/VLDA nonachievers, 23.10% (398/1723) and 10.24% (236/2304) missed MDA/VLDA achievement by 1 criterion, respectively. At the follow-up registry visit, pain was the most commonly unmet criterion across the overall MDA nonachiever (95.41%) and VLDA nonachiever (87.02%) cohorts. Other commonly unmet criteria were the patient global assessment of arthritis and psoriasis (MDA nonachievers, 89.32%; VLDA nonachievers, 75.87%) and Health Assessment Questionnaire–Disability Index (MDA nonachievers, 80.91%; VLDA nonachievers, 67.01%).
Conclusion
Despite receiving b/tsDMARD treatment for PsA, most patients did not achieve MDA or VLDA, the most commonly unmet criteria being pain and other patient-reported outcomes. These findings indicate opportunities to improve PsA management.